Imidazothiazole

Abstract

Recent research on cancer therapy has revealed that the emergence of malignant cells is caused by several enzyme alterations. such include kinase inhibitors of ErB4 (HER4), B-Raf kinase, and indoleamine 2,3-dioxygenase 1 (IDO1). Researchers discovered that drugs based on imidazothiazoles, and their analogues exhibit more robust anticancer action by inhibiting these enzymatic receptors. In recent times, imidazothiazole scaffold is broadly explored for its anticancer activity, which acts through various mechanisms such as EGFR, B-RAF, DHFR kinase inhibition and tubulin polymerization inhibition and other molecular mechanisms of action. Due to their feasible synthetic accessibility and promising pharmacological profile, it has attracted various medicinal chemists to explore and develop imidazothiazole derivatives as potent and safe anticancer agents. In the present book chapter, we have reviewed various potent imidazothiazole scaffold-based derivatives reported as anticancer agents, their synthetic strategies, with their future perspective.